Labopharm Inc.
News and overview for Labopharm Inc.
Labopharm Reports Results for Third Quarter Fiscal 2009 [Press Release]
PRNewswire | 16 days 16 hours 54 minutes ago
- Company Advances Plans to Realize the Benefits of Commercialization: Streamlines Operations to Focus on Nearer-Term Commercial Opportunities -
Labopharm to present at Dundee Emerging Growth Summit [Press Release]
PRNewswire | 2 days 18 hours 29 minutes ago
LAVAL, QC, Nov. 20 /PRNewswire-FirstCall/ - Labopharm Inc.
Labopharm's novel trazodone formulation subject of publication in peer-reviewed medical journal [Press Release]
PRNewswire | 12 days 12 hours 44 minutes ago
LAVAL, QC, Nov. 10 /PRNewswire-FirstCall/ - Labopharm Inc.
Labopharm posts wider Q3 loss as revenue falls 30 pct
Canada.com | 16 days 18 hours 14 minutes ago
Labopharm Inc posted a wider quarterly loss, as the Canadian drugmaker earned lower licensing revenue from its once-daily tramadol pain treatment and said it would cut about 35 jobs under a plan to streamline operations.
Labopharm Reports Results for Second Quarter Fiscal 2009 [Press Release]
PRNewswire | 108 days 1 hour 27 minutes ago
- Quarter Marked by Launch of RYZOLT(TM) in U.S. - - Company to Submit Response to FDA for Novel Trazodone Formulation Next Week -
Labopharm cuts 35 jobs
Globe and Mail (Toronto), The | 16 days 17 hours 42 minutes ago
Makes move after recording wider third-quarter loss
Labopharm completes distribution and supply agreement with Grunenthal for twice-daily tramadol-acetaminophen for a number of European countries [Press Release]
PRNewswire | 45 days 23 hours 57 minutes ago
- The Agreement Includes Up-Front and Milestone Payments of up to 7.5 Million Euros -
Labopharm to host conference call Friday, November 6, 2009 at 10:00 a.m. (ET) [Press Release]
PRNewswire | 24 days 19 hours 47 minutes ago
- Management to discuss third quarter financial results -
Labopharm to present data on its novel trazodone formulation at three upcoming international medical meetings [Press Release]
PRNewswire | 74 days 18 hours 27 minutes ago
LAVAL, QC, Sept. 9 /PRNewswire-FirstCall/ - Labopharm Inc.
Labopharm's response for novel trazodone formulation accepted by FDA as complete - Designated as Class 2 resubmission [Press Release]
PRNewswire | 89 days 15 hours 57 minutes ago
- New PDUFA action date assigned -
Labopharm receives notice of ANDA submission with paragraph IV certification for generic of Ryzolt(TM) [Press Release]
PRNewswire | 54 days 1 hour 26 minutes ago
LAVAL, QC, Sept. 30 /PRNewswire-FirstCall/ - Labopharm Inc.
Labopharm files New Drug Submission with Health Canada for novel antidepressant [Press Release]
PRNewswire | 110 days 1 hour 26 minutes ago
LAVAL, QC, Aug. 5 /PRNewswire-FirstCall/ - Labopharm Inc.
Labopharm announces that its trazodone API supplier has resolved outstanding manufacturing issues with the FDA [Press Release]
PRNewswire | 46 days 23 hours 26 minutes ago
LAVAL, QC, Oct. 7 /PRNewswire-FirstCall/ - Labopharm Inc.
Labopharm comments on judgment in Purdue patent litigation [Press Release]
PRNewswire | 97 days 23 hours 27 minutes ago
LAVAL, QC, Aug. 17 /PRNewswire-FirstCall/ - Labopharm Inc.
Labopharm submits response to FDA for novel antidepressant [Press Release]
PRNewswire | 103 days 19 hours 57 minutes ago
LAVAL, QC, Aug. 11 /PRNewswire-FirstCall/ - Labopharm Inc.
Sign up for AdvaMed SmartBrief
Company Overview
| Company: | Labopharm Inc. |
|---|---|
| Industry: | Drug Delivery Systems |
| Website: | http://www.labopharm.com |
Drugs can control diseases, but Labopharm works to control the drugs. The company creates controlled-release drug delivery systems to turn new and existing drugs into once-a-day formulations. Its platform product Contramid is a controlled-release system for oral solid dosage forms. In recent years the company has shifted its strategy from licensing the Contramid platform to other pharmaceutical companies to developing its own products. Labopharm's lead product combines Contramid with tramadol, an analgesic used for moderate to severe pain and marketed as Ryzolt. The company also licenses its Contramid platform for Gruppo Agelini's antidepressant Trazodone.
Key Numbers
| Sales in U.S. Dollars (mil.) | 18 (2008) |
|---|---|
| One-year % Growth in Sales | -6.9 (2008) |
| Net Income in U.S. Dollars (mil.) | -33.1 (2008) |
| One-year % Growth in Net Income | 0.0 (2008) |
| Number of Employees | 168 (2008) |
| One-year % Growth in Number of Employees | 82.6 (2008) |
| Fiscal Year-End | December |